US20060024329A1 - Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2. - Google Patents
Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2. Download PDFInfo
- Publication number
- US20060024329A1 US20060024329A1 US10/935,494 US93549404A US2006024329A1 US 20060024329 A1 US20060024329 A1 US 20060024329A1 US 93549404 A US93549404 A US 93549404A US 2006024329 A1 US2006024329 A1 US 2006024329A1
- Authority
- US
- United States
- Prior art keywords
- nucleotide sequence
- heterologous nucleotide
- recombinant chv
- expresses
- insertion site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000680578 Canid alphaherpesvirus 1 Species 0.000 title claims abstract description 193
- 241001559187 Human rubulavirus 2 Species 0.000 title claims abstract description 53
- 229960005486 vaccine Drugs 0.000 title abstract description 19
- 201000010099 disease Diseases 0.000 title description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 11
- 206010037742 Rabies Diseases 0.000 title description 2
- 239000002773 nucleotide Substances 0.000 claims abstract description 146
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 146
- 238000003780 insertion Methods 0.000 claims abstract description 106
- 230000037431 insertion Effects 0.000 claims abstract description 106
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 73
- 241000712083 Canine morbillivirus Species 0.000 claims abstract description 64
- 239000000427 antigen Substances 0.000 claims abstract description 60
- 102000036639 antigens Human genes 0.000 claims abstract description 60
- 108091007433 antigens Proteins 0.000 claims abstract description 60
- 108091029795 Intergenic region Proteins 0.000 claims abstract description 48
- 241000711798 Rabies lyssavirus Species 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 108700019832 Borrelia burgdorferi OspB Proteins 0.000 claims abstract 25
- 101001086191 Borrelia burgdorferi Outer surface protein A Proteins 0.000 claims abstract 25
- 101100135135 Borrelia burgdorferi ospB gene Proteins 0.000 claims abstract 25
- 241000701931 Canine parvovirus Species 0.000 claims abstract 25
- 101001062679 Phocine distemper virus Fusion glycoprotein F0 Proteins 0.000 claims abstract 25
- 230000001900 immune effect Effects 0.000 claims abstract 5
- 230000028993 immune response Effects 0.000 claims abstract 4
- 230000001939 inductive effect Effects 0.000 claims abstract 4
- 102000000505 Ribonucleotide Reductases Human genes 0.000 claims description 46
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims description 46
- 241000282465 Canis Species 0.000 claims description 21
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 238000012217 deletion Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 7
- 230000002519 immonomodulatory effect Effects 0.000 claims description 7
- 230000008488 polyadenylation Effects 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 108091026890 Coding region Proteins 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 241001529936 Murinae Species 0.000 claims description 4
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 abstract description 17
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 abstract description 17
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 abstract description 17
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 abstract description 17
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 abstract description 17
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 abstract description 17
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 abstract description 17
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 abstract description 17
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 abstract description 17
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 abstract description 17
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 abstract description 17
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 abstract description 17
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 abstract description 17
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 abstract description 17
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 abstract description 17
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 abstract description 17
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 abstract description 17
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 abstract description 17
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 abstract description 17
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 abstract description 17
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 abstract description 17
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 abstract description 17
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 abstract description 17
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 abstract description 17
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 abstract description 17
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 abstract description 17
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 abstract description 17
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 abstract description 17
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 abstract description 17
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 abstract description 17
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 abstract description 17
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 abstract description 17
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 abstract description 17
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 abstract description 17
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 abstract description 17
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 abstract description 17
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 abstract description 17
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 abstract description 17
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 abstract description 17
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 abstract description 17
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 abstract description 17
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 abstract description 17
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 abstract description 17
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 abstract description 17
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 abstract description 17
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 abstract description 17
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 abstract description 17
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 abstract description 17
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 abstract description 17
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 abstract description 17
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 abstract description 17
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 abstract description 17
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 abstract description 17
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 abstract description 12
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 abstract description 12
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 abstract description 12
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 abstract description 12
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 abstract description 12
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 abstract description 12
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 abstract description 12
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 abstract description 12
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 abstract description 12
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 abstract description 12
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 abstract description 12
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 abstract description 12
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 abstract description 12
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 abstract description 12
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 abstract description 12
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 abstract description 12
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 abstract description 12
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 abstract description 12
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 abstract description 12
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 abstract description 12
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 abstract description 12
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 abstract description 12
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 abstract description 12
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 abstract description 12
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 abstract description 12
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 abstract description 12
- 108020004440 Thymidine kinase Proteins 0.000 abstract description 12
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 abstract description 12
- 239000013612 plasmid Substances 0.000 description 95
- 239000012634 fragment Substances 0.000 description 75
- 108091034117 Oligonucleotide Proteins 0.000 description 39
- 238000010276 construction Methods 0.000 description 30
- 241000700605 Viruses Species 0.000 description 25
- 239000013598 vector Substances 0.000 description 20
- 101150039660 HA gene Proteins 0.000 description 16
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 241000701022 Cytomegalovirus Species 0.000 description 12
- 241000282472 Canis lupus familiaris Species 0.000 description 11
- 102000006601 Thymidine Kinase Human genes 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 101000743335 Haemophilus phage HP1 (strain HP1c1) Probable terminase, endonuclease subunit Proteins 0.000 description 8
- 101000820589 Homo sapiens Succinate-hydroxymethylglutarate CoA-transferase Proteins 0.000 description 8
- 101000790838 Klebsiella pneumoniae UPF0053 protein in cps region Proteins 0.000 description 8
- 101000748499 Rhodobacter capsulatus Uncharacterized 104.1 kDa protein in hypE 3'region Proteins 0.000 description 8
- 102100021652 Succinate-hydroxymethylglutarate CoA-transferase Human genes 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 101000976893 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 14.1 kDa protein in cox-rep intergenic region Proteins 0.000 description 7
- 101000786921 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 26.0 kDa protein in rep-hol intergenic region Proteins 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 101000770899 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 24.3 kDa protein Proteins 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 101150082239 G gene Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000007758 minimum essential medium Substances 0.000 description 6
- 101150034814 F gene Proteins 0.000 description 5
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 5
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 5
- 102100024407 Jouberin Human genes 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 108700002232 Immediate-Early Genes Proteins 0.000 description 3
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 3
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 3
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000589969 Borreliella burgdorferi Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101710197985 Probable protein Rev Proteins 0.000 description 2
- 241000711841 Rabies virus ERA Species 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- 101000787133 Acidithiobacillus ferridurans Uncharacterized 12.3 kDa protein in mobL 3'region Proteins 0.000 description 1
- 101000787132 Acidithiobacillus ferridurans Uncharacterized 8.2 kDa protein in mobL 3'region Proteins 0.000 description 1
- 101000827262 Acidithiobacillus ferrooxidans Uncharacterized 18.9 kDa protein in mobE 3'region Proteins 0.000 description 1
- 241000700587 Alphaherpesvirinae Species 0.000 description 1
- 101000811747 Antithamnion sp. UPF0051 protein in atpA 3'region Proteins 0.000 description 1
- 101000666833 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.8 kDa protein in FGF-VUBI intergenic region Proteins 0.000 description 1
- 101000977023 Azospirillum brasilense Uncharacterized 17.8 kDa protein in nodG 5'region Proteins 0.000 description 1
- 101000977027 Azospirillum brasilense Uncharacterized protein in nodG 5'region Proteins 0.000 description 1
- 101000827603 Bacillus phage SPP1 Uncharacterized 10.2 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 1
- 101000827607 Bacillus phage SPP1 Uncharacterized 8.5 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 1
- 101000961975 Bacillus thuringiensis Uncharacterized 13.4 kDa protein Proteins 0.000 description 1
- 101000962005 Bacillus thuringiensis Uncharacterized 23.6 kDa protein Proteins 0.000 description 1
- 101000961984 Bacillus thuringiensis Uncharacterized 30.3 kDa protein Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 101000964407 Caldicellulosiruptor saccharolyticus Uncharacterized 10.7 kDa protein in xynB 3'region Proteins 0.000 description 1
- 241000711506 Canine coronavirus Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 101000644901 Drosophila melanogaster Putative 115 kDa protein in type-1 retrotransposable element R1DM Proteins 0.000 description 1
- 101000785191 Drosophila melanogaster Uncharacterized 50 kDa protein in type I retrotransposable element R1DM Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101000747704 Enterobacteria phage N4 Uncharacterized protein Gp1 Proteins 0.000 description 1
- 101000747702 Enterobacteria phage N4 Uncharacterized protein Gp2 Proteins 0.000 description 1
- 101000861206 Enterococcus faecalis (strain ATCC 700802 / V583) Uncharacterized protein EF_A0048 Proteins 0.000 description 1
- 101000769180 Escherichia coli Uncharacterized 11.1 kDa protein Proteins 0.000 description 1
- 101000758599 Escherichia coli Uncharacterized 14.7 kDa protein Proteins 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000768777 Haloferax lucentense (strain DSM 14919 / JCM 9276 / NCIMB 13854 / Aa 2.2) Uncharacterized 50.6 kDa protein in the 5'region of gyrA and gyrB Proteins 0.000 description 1
- 101710126256 Hydrolase in agr operon Proteins 0.000 description 1
- 101000607404 Infectious laryngotracheitis virus (strain Thorne V882) Protein UL24 homolog Proteins 0.000 description 1
- 101000735632 Klebsiella pneumoniae Uncharacterized 8.8 kDa protein in aacA4 3'region Proteins 0.000 description 1
- 101000768930 Lactococcus lactis subsp. cremoris Uncharacterized protein in pepC 5'region Proteins 0.000 description 1
- 241000222697 Leishmania infantum Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 101000976301 Leptospira interrogans Uncharacterized 35 kDa protein in sph 3'region Proteins 0.000 description 1
- 101000976302 Leptospira interrogans Uncharacterized protein in sph 3'region Proteins 0.000 description 1
- 101000778886 Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai (strain 56601) Uncharacterized protein LA_2151 Proteins 0.000 description 1
- 101000977786 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 9.7 kDa protein in PE 3'region Proteins 0.000 description 1
- 241000710118 Maize chlorotic mottle virus Species 0.000 description 1
- 101000658690 Neisseria meningitidis serogroup B Transposase for insertion sequence element IS1106 Proteins 0.000 description 1
- 101150009852 ORF2 gene Proteins 0.000 description 1
- 101150062176 ORF5 gene Proteins 0.000 description 1
- 108700006640 OspA Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 101000748660 Pseudomonas savastanoi Uncharacterized 21 kDa protein in iaaL 5'region Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101000584469 Rice tungro bacilliform virus (isolate Philippines) Protein P1 Proteins 0.000 description 1
- 101001121571 Rice tungro bacilliform virus (isolate Philippines) Protein P2 Proteins 0.000 description 1
- 101001113905 Rice tungro bacilliform virus (isolate Philippines) Protein P4 Proteins 0.000 description 1
- 108050007496 Shikimate kinase 2 Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101000818100 Spirochaeta aurantia Uncharacterized 12.7 kDa protein in trpE 5'region Proteins 0.000 description 1
- 101000818096 Spirochaeta aurantia Uncharacterized 15.5 kDa protein in trpE 3'region Proteins 0.000 description 1
- 101000818098 Spirochaeta aurantia Uncharacterized protein in trpE 3'region Proteins 0.000 description 1
- 101000766081 Streptomyces ambofaciens Uncharacterized HTH-type transcriptional regulator in unstable DNA locus Proteins 0.000 description 1
- 101001026590 Streptomyces cinnamonensis Putative polyketide beta-ketoacyl synthase 2 Proteins 0.000 description 1
- 101001037658 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) Glucokinase Proteins 0.000 description 1
- 241000709710 Swine vesicular disease virus Species 0.000 description 1
- 101000804403 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HIT-like protein Synpcc7942_1390 Proteins 0.000 description 1
- 101000750910 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HTH-type transcriptional regulator Synpcc7942_2319 Proteins 0.000 description 1
- 101000750896 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized protein Synpcc7942_2318 Proteins 0.000 description 1
- 101000644897 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) Uncharacterized protein SYNPCC7002_B0001 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101150093578 VP2 gene Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 101000916321 Xenopus laevis Transposon TX1 uncharacterized 149 kDa protein Proteins 0.000 description 1
- 101000916336 Xenopus laevis Transposon TX1 uncharacterized 82 kDa protein Proteins 0.000 description 1
- 101001000760 Zea mays Putative Pol polyprotein from transposon element Bs1 Proteins 0.000 description 1
- 101000760088 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 20.9 kDa protein Proteins 0.000 description 1
- 101000678262 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 65 kDa protein Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16741—Use of virus, viral particle or viral elements as a vector
- C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to vaccines, preferably for dogs, produced from recombinant canine herpesviruses, and to the methods for obtaining and preparing these recombinant viruses.
- the present invention relates more especially to recombinant canine herpesviruses comprising an expression cassette for one or more foreign gene(s).
- Canine herpesvirosis is caused by the canine herpesvirus (CHV).
- CHV canine herpesvirus
- the canine herpesvirus (CHV) is classified in the Alphaherpesvirinae family. This herpesvirus is a major pathogen for neonatal puppies.
- Canine herpesvirosis manifests itself chiefly in a haemorrhagic disease in puppies, and in a benign disease of the upper respiratory apparatus in adult dogs. There are at present no vaccines for protecting puppies against canine herpesvirosis.
- domestic dogs are exposed to numerous other diseases, and the development of a vaccinal vector capable of expressing different antigens of canine pathogenic agents would enable the efficacy of vaccination programmes to be simplified and improved, especially for puppies in breeding kennels.
- pathogenic agents of importance for dogs the Carre's disease virus, the Rubarth's hepatitis virus, the rabies virus, the canine parvovirosis virus, the canine coronavirus, the parainfluenza virus type 2, Bordetella bronchiseptica, Borrelia burgdorferi, Leptospira spp. and Leishmania infantum may be mentioned.
- the inventors have succeeded in determining several regions which are non-essential for replication in vitro, which have proved useful for the construction of recombinant CHV viruses.
- the inventors are hence in a position to put forward for the first time the CHV virus as a vaccination vector for dogs.
- the vaccinal vectors according to the invention had particular advantages for the vaccination of dogs.
- the canine herpesvirus is very species-specific and possesses a large genome containing several potential insertion sites and permitting the simultaneous insertion of several expression cassettes for foreign genes. This affords the possibility of vaccinating dogs at the same time against different canine pathogenic agents using a single recombinant virus.
- the main objective of the invention is to provide a vaccinal vector permitting the expression of immunogens of canine pathogens for the purpose of protecting dogs against the main canine infectious diseases.
- Another objective of the invention is to provide such a vector permitting the vaccination of dogs, and especially puppies having maternal antibodies, via the mucosal, in particular the oral, nasal or conjunctival, route.
- Yet another objective of the invention is to provide such a vector which permits vaccination at the same time against herpesvirosis in puppies.
- the subject of the present invention is a recombinant live vaccine using as vector a canine herpesvirus comprising and expressing at least one nucleotide sequence coding for a polypeptide, this sequence being inserted into a site which is non-essential for replication in vitro.
- the inventors have isolated and analysed a genomic fragment of the CHV virus, on which they have characterized 5 open reading frames (ORF1 to ORF5), among which two (ORF3 and ORF5) have proved to be non-essential for replication in vitro. Moreover, the inventors have found that other regions of the CHV genome could also be used to insert foreign genes. These insertion sites are: thymidine kinase gene (CHV TK ORF) (Rémond M. et al. Virus Research. 1995. 39. 341-354.) and sequence situated between the CHV ORF19 and the CHV ORF22 (Rémond M. et al. J. Gen. Virol. 1996. 76. 37-48). These sites are described more precisely in the examples of the present invention.
- CHV TK ORF thymidine kinase gene
- the inserted sequence codes for an antigenic polypeptide, and preferentially for an antigenic polypeptide of a canine pathogenic agent. It is also possible to insert the sequences coding for immunomodulatory proteins such as cytokines. According to an advantageous variant, it is possible to use in combination a sequence coding for a cytokine, or the like, and a sequence coding for an antigen. If need be, several cytokine sequences can be used in combination with one another, optionally in combination with one or more sequences coding for antigens.
- the insertion into the sites is carried out by simple insertion (without deletion), or after partial or total deletion of the ORF or ORFs used as insertion sites.
- CHV strain F205 which was isolated by L. Carmichael (Proc. Soc. Exp. Biol. Med. 1965. 120. 644-650).
- CMV IE promoter is understood to mean, in particular, a fragment such as is given in the examples, as well as the subfragments thereof retaining the same promoter activity.
- the CMV IE promoter can be the human (HCMV IE) promoter or the murine (MCMV IE) promoter, or alternatively a CMV IE promoter of another origin, for example rat, guinea pig or porcine CMV.
- At least two nucleotide sequences may be inserted into one site under the control of different promoters.
- the latter may be, in particular, CMV IE promoters of different origins.
- another promoter is used in combination with the CMV IE promoter in such a way that the two promoters have their 5′ ends adjacent and that the transcriptions initiated from these two promoters take place in opposite directions.
- This particular arrangement enables two nucleotide sequences to be inserted into the same site, one under the control of the CMV IE promoter and the other under that of the promoter used in combination with it.
- This construction is noteworthy from the fact that the presence of the CMV IE promoter, and in particular of its enhancer portion, can activate the transcription induced by the promoter used in combination.
- a promoter used in combination there may be mentioned, for example, a CMV promoter of different species from the first promoter. It is also possible to envisage other promoters, such as the Marek's disease virus (MDV) RNA1.8 promoter (G. Bradley et al. J. Virol. 1989. 63. 2534-2542).
- MDV Marek's disease virus
- the nucleotide sequence inserted into the CHV vector in order to be expressed can be any sequence coding for an antigenic polypeptide of a canine pathogenic agent capable, when expressed under the favourable conditions obtained by the invention, of bringing about an immunization leading to an effective protection of the vaccinated animal against the pathogenic agent.
- the nucleotide sequences coding for the antigens of interest for a given disease, in particular the viral, bacterial or parasitic diseases mentioned above, may hence be inserted under the conditions described by the present invention.
- CDV Carré's disease virus
- nucleotide sequences coding for antigens or fragments of antigens of the rabies virus especially the G gene (Patents FR-A-2,515,685 and EP-A-162,757), of the canine parvovirosis virus (VP2 gene) (Parrish C. et al. J. Virol. 1991. 65. 6544-6552) or of the parainfluenza virus type 2 (HA and/or F genes).
- VP2 gene canine parvovirosis virus
- HA and/or F genes parainfluenza virus type 2
- sequences coding for Borrelia burgdorferi antigens especially the genes coding for the OspA and OspB antigens (Bergström S. et al. Mol. Microbiol. 1989. 3. 479-486).
- a typical case of the invention is a vaccine comprising a nucleotide sequence coding for an antigen of the Carré's disease virus under the control of CMV IE, and a nucleotide sequence coding for an antigen of another canine viral disease, in particular the ones mentioned above, under the control of the other promoter.
- heterologous sequences and their associated promoters may be inserted more conventionally in tandem into the insertion locus, that is to say according to the same transcription direction.
- IVS internal ribosome entry site
- SVDV swine vesicular disease virus
- EMCV encephalomyocarditis virus
- FMDV aphthous fever virus
- the cassette for expression of two genes would hence have the following minimum structure: promoter—gene 1—IRES—gene 2—polyadenylation signal.
- the recombinant live vaccine according to the invention may hence comprise, inserted into the insertion locus, an expression cassette comprising in succession a promoter, two or more genes separated in pairs by an IRES, and a polyadenylation signal.
- insertion into the locus it is possible to carry out one or more other insertions, one or more mutations or one or more deletions elsewhere in the genome. In all cases, insertion into a locus other than the one described in the invention enables other genes to be expressed.
- the use of the recombinant viruses according to the invention enables dogs to be protected against one or more of the diseases mentioned above, and at the same time against canine herpesvirosis.
- the subject of the present invention is also a polyvalent vaccine formula comprising, as a mixture or to be mixed, at least two recombinant live vaccines as defined above, these vaccines comprising different inserted sequences isolated, in particular, from different pathogens.
- These vaccine formulae contain dosages and/or vehicles which are suited to the administration route.
- the subject of the present invention is also CHV viruses modified in at least one of the sites indicated.
- Its subject is also a method of vaccination, especially of dogs, in which an effective amount of a vaccine as defined above is administered via any parenteral or mucosal route, but preferably via the mucosal, in particular the oral and/or nasal, route.
- the vaccinal dose will preferably be between 10 2 CCID50 and 10 7 CCID50.
- the dose for the parenteral route will be between 10 4 CCID50 and 10 7 CCID50, and for the oral and/or nasal route, between 10 2 CCID50 and 10 5 CCID50.
- the vaccine is effective in general after a single administration via the oral and/or nasal route. However, repeated administrations may be necessary.
- the subject of the present invention is also the DNA fragments comprising all or part of the sequence defined by positions 1 to 6216 on SEQ ID No. 1 ( FIG. 1 ), in particular all or part of the ORF3 site defined and/or of the flanking sequences located upstream and downstream of this site, which fragments will be useful as flanking arms for the techniques of homologous recombination with the genome of the CHV virus chosen as parent virus.
- the invention also relates to the variants of these fragments which correspond to the equivalent sequences of the other strains of CHV.
- the expert is entirely free to choose the regions serving as flanking arms in connection with the type of insertion (with or without deletion) or of deletion (partial or total) chosen.
- the flanking arms may thus have from 100 to 800 base pairs, but can be larger if necessary.
- a further subject of the invention is a method of preparation of the vectors and vaccines according to the invention, as emerges from the description of the vaccines, by insertion of genes of interest into the insertion site.
- FIG. 1 Sequence of the CHV region (6216 base pairs) and translation of the different open reading frames (ORFs) present in this sequence (ORF1 to ORF5).
- FIG. 2 Plasmid pPB200 (donor plasmid for the insertion of expression cassettes into the CHV ORF3 site).
- FIG. 3 Construction of the plasmid pP3202 (donor plasmid for the insertion of expression cassettes into the CHV ORF5 site).
- FIG. 4 Construction of the plasmid pPB204 (donor plasmid for the insertion of expression cassettes into the CHV TK site).
- FIG. 5 Construction of the plasmid pPB206 (donor plasmid for the insertion of expression cassettes into the site situated between the CHV ORF19 and CHV ORF22 genes).
- FIG. 6 Construction of the plasmid pPB208 (expression cassette for the CDV HA gene).
- FIG. 7 Construction of the plasmid pPB210 (expression cassette for the CDV F gene).
- FIG. 8 Construction of the plasmid pPB213 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF3 site).
- FIG. 9 Construction of the plasmid pPB214 (donor plasmid for the insertion of the cassette for the expression of the CDV F gene into the CHV ORF3 site).
- FIG. 10 Plasmid pPB200′
- FIG. 11 Construction of the plasmid pPB212 (cassette for the expression of the rabies virus G gene).
- FIG. 12 Construction of the plasmid pPB125 (donor plasmid for the insertion of the cassette for the expression of the rabies virus G gene into the CHV ORF3 site).
- FIG. 13 Construction of the plasmid pPB216 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF5 site).
- FIG. 14 Construction of the plasmid pPB217 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the CHV TK site).
- FIG. 15 Construction of the plasmid pPB218 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the site situated between the CHV ORF19 and CHV ORF22 genes).
- the virus used as parent virus is the canine herpesvirus strain F205 (also known as the Carmichael strain). This strain was obtained from Dr. L. Carmichael (Cornell University, NY), who isolated it and described its biological characteristics (Proc. Soc. Exp. Biol. Med. 1965. 120. 644-650).
- the conditions of culture of this virus are as follows: MDCK (Madin-Darby canine kidney ATCC CCL34) cells cultured in Eagle's minimum essential medium (MEM medium) are inoculated with the CHV strain F205 using a multiplicity of infection of 1. The infected cells are then incubated at 37° C. for approximately 36 hours until a complete cytopathic effect is seen.
- the supernatant and the lysed cells are harvested, and the whole of the viral suspension is centrifuged at 1000 g for 10 minutes at +4° C. to remove cell debris.
- the viral particles are then harvested by ultracentrifugation at 400,000 g for 1 hour at +4° C.
- the pellet is taken up in a minimum volume of buffer (10 mM Tris, 1 mM EDTA).
- This concentrated viral suspension is treated with proteinase K (100 ⁇ g/ml final) in the presence of sodium dodecyl sulphate (SDS) (0.5% final) for 2 hours at 37° C.
- SDS sodium dodecyl sulphate
- the viral DNA is then extracted with a phenol/chloroform mixture and thereafter precipitated with 2 volumes of absolute ethanol. After one night at ⁇ 20° C., the precipitated DNA is centrifuged at 10,000 g for 15 minutes at +4° C. The DNA pellet is dried and then taken up in a minimum volume of sterile ultra
- the purified genomic DNA of the CHV virus strain F205 was digested with the restriction enzymes ScaI and XhoI, and the approximately 6200-bp ScaI-XhoI fragment was cloned into the vector pBlueScript SKII+ (Stratagene Ref. 212205), previously digested with ScaI and XhoI, to give the plasmid pPB154.
- the XhoI-ScaI fragment cloned into plasmid pPB154 was sequenced completely on both strands to generate the 6216-bp sequence of FIG. 1 (SEQ ID No. 1).
- FIG. 1 Several open reading frames larger than 65 amino acids in size were identified on this sequence ( FIG. 1 ):
- the first reading frame (ORF1) (positions 1353-157) occurs on the complementary strand and codes for a polypeptide of 398 amino acids (SEQ ID No. 2).
- the second reading frame (ORF2) (positions 1708-2970) codes for a polypeptide of 420 amino acids (SEQ ID No. 3).
- the third reading frame (ORF3) (positions 3040-4242) codes for a polypeptide of 400 amino acids (SEQ ID No. 4).
- the fourth reading frame (positions 4374-5753) codes for a polypeptide of 459 amino acids (SEQ ID No. 5).
- the fifth reading frame (ORF5) (positions 5872-6216) is incomplete and codes for a truncated protein of 115 amino acids (SEQ ID No. 6).
- Plasmid pPB154 (9121 bp) (Example 2) was digested with HindIII and SpeI to isolate the 620-bp HindIII-SpeI fragment (fragment A). Plasmid pPB154 was digested with EcoRI and SpeI to isolate the 659-bp EcoRI-SpeI fragment (fragment B). The fragments A and B were ligated together with the vector pGEM4Z (Promega Ref. P2161), previously digested with EcoRI and HindIII, to give the plasmid pPB199 (4096 bp).
- pGEM4Z Promega Ref. P2161
- Plasmid pPB199 was then digested with SpeI, treated with alkaline phosphatase and then ligated with the multiple cloning site obtained by hybridization of the following 2 oligonucleotides: JCA070 (33 mer) (SEQ ID No. 7) 5′ CTAGTCCAGCAAGGTGGATCGATATCGGGCCCA 3′ JCA071 (33 mer) (SEQ ID No. 8) 5′ CTAGTGGGCCCGATATCGATCCACCTTGCTGGA 3′ to give plasmid pPB200 (4129 bp).
- the sequence of the CHV ORF5 gene was published recently (Limbach K. et al. J. Gen. Virol. 1994. 75. 2029-2039).
- a PCR reaction was carried out with the genomic DNA of the CHV virus strain F205 (Example 1) and with the following oligonucleotides: JCA072 (22 mer) (SEQ ID No. 9) 5′ CAGCTTTATGTTTTTATTGTTC 3′ JCA073 (29 mer) (SEQ ID No. 10) 5′ AAAGAATTCTACAACTGTTTAATAAAGAC 3′
- Plasmid pPB201 was then digested with ScaI and PvuII and thereafter ligated with a multiple cloning site obtained by hybridization of the following 2 oligonucleotides: JCA074 (36 mer) (SEQ ID No.
- TK CHV thymidine kinase
- This fragment was digested with HpaI and HindIII to isolate a 1019-bp HpaI-HindIII fragment.
- This fragment was ligated with the vector pSP73 (Promega Ref. P2221), previously digested with EcoRV and HindIII, to give the plasmid pPB203 (3423 bp).
- Plasmid pPB203 was then digested with EcoRI and StyI and thereafter ligated with a multiple cloning site obtained by hybridization of the following 2 oligonucleotides: JCA078 (36 mer) (SEQ ID No. 15) 5′ AATTCCCAGCTACATGGGATATCGGGCCCATCGATC 3′ JCA079 (36 mer) (SEQ ID No. 16) 5′ CAAGGATCGATGGGCCCGATATCCCATGTAGCTGGG 3′ to give plasmid pPB204 (3399 bp).
- a PCR reaction was carried out with the genomic DNA of the CHV virus strain F205 (Example 1) and with the following oligonucleotides: JCA080 (36 mer) (SEQ ID No. 17) 5′ GGAGATCTAGTAAATTAAATAGTAATTCATTTAATG 3′ JCA081 (33 mer) (SEQ ID No. 18) 5′ CAGTCGCGAAGATGAAAATAAAATCCATCGAAG 3′
- Plasmid pPB205 was then digested with MfeI and thereafter partially digested with SspI in order to isolate the 3512-bp MfeI-SspI fragment.
- JCA082 38 mer
- SEQ ID No. 19 5′ AATTGGCAGCTACATGGGATATCGGGCCCATCGATAAT 3′ JCA083 (34 mer)
- JCA083 34 mer
- SEQ ID No. 20 5′ ATTATCGATGGGCCCGATATCGGATGTAGCTGGC 3′ to give plasmid pPB206 (3548 bp).
- the CDV strain Onderstepoort (Mitchell W. et al. J. Virol. Meth. 1987. 18. 121-131) was cultured on MDCK (Madin-Darby canine kidney) cells in DMEM medium (Gibco). After purification of the virus, the genomic viral RNA was isolated using the guanidinium thiocyanate/phenol-chloroform extraction technique (Chomczynski P. and Sacchi N., Anal. Biochem. 1987. 162. 156-159).
- oligonucleotides containing restriction sites at their 5′ ends to facilitate the cloning of the amplified fragments
- the reverse transcription (RT) reaction and polymerase chain amplification (PCR) were performed according to the standard techniques (Sambrook J. et al. 1989). Each RT-PCR reaction was carried out with a pair of specific amplimers and taking as template the extracted viral genomic RNA.
- the amplified complementary DNA was extracted with phenol/chloroform/isoamyl alcohol (25:24:1) before being digested with the restriction enzymes and cloned into the appropriate vector.
- the plasmid pCMVB (Clontech Ref. 6177-1) was digested with EcoRI and NotI to isolate an 818-bp EcoRI-NotI fragment containing the promoter region of the human cytomegalovirus immediate-early gene (fragment A).
- the fragments A and B were ligated together with the vector pGEM-7Zf+ (Promega Cat # P2251), previously digested with EcoRI and KpnI, to give the plasmid pPB207 (5634 bp).
- a PCR reaction was carried out with plasmid pCMVB and with the following oligonucleotides: PB088 (30 mer) (SEQ ID No. 23) 5′ TTGGGTACCGCCTCGACTCTAGGCGGCCGC 3′ PB089 (32 mer) (SEQ ID No. 24) 5′ TTGGGTACCGGATCCGAAAAAACCTCCCACAC 3′ to obtain a 244-bp PCR fragment containing the polyadenylation signal of the SV40 virus early gene. This fragment was digested with KpnI to isolate a 233-bp KpnI-KpnI fragment.
- Plasmid PCMVB (Clontech Ref. 6177-1) was digested with EcoRI and NotI to isolate an 818-bp EcoRI-NotI fragment containing the promoter region of the human cytomegalovirus immediate-early gene (fragment A).
- the fragments A and B were ligated together with the vector pGEM-7Zf+ (Promega Ref. P2251), previously digested with EcoRI and KpnI, to give the plasmid pPB209 (5808 bp).
- PCR reaction was carried out with plasmid pCMVB and with the following oligonucleotides: PB088 (30 mer) (SEQ ID No. 23) 5′ TTGGGTACCGCCTCGACTCTAGGCGGCCGC 3′ PB089 (32 mer) (SEQ ID No. 24) 5′ TTGGGTACCGGATCCGAAAAAACCTCCCACAC 3′ to obtain a 244-bp PCR fragment containing the polyadenylation signal of the SV40 virus early gene. This fragment was digested with KpnI to isolate a 233-bp KpnI-KpnI fragment. This fragment was then ligated with plasmid pPB209, previously digested with KpnI, to give plasmid pPB210 (6041 bp).
- Plasmid pPB208 (Example 7.1.) was digested with ApaI and ClaI to isolate a 2920-bp ApaI-ClaI fragment containing the cassette for the expression of the CDV virus HA gene. This fragment was then ligated with plasmid pPB200 (Example 3), previously digested with ApaI and ClaI, to give plasmid pPB213 (7043 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF3 site.
- Plasmid pPB210 (Example 7.2.) was digested with ApaI and ClaI to isolate a 3100-bp ApaI-ClaI fragment containing the cassette for the expression of the CDV virus F gene. This fragment was then ligated with plasmid pPB200 (Example 3), previously digested with ApaI and ClaI, to give plasmid pPB214 (7217 bp). This plasmid permits the insertion of the cassette for the expression of the CDV F gene into the CHV ORF3 site.
- Plasmid pPB199 (Example 3) was digested with SpeI, treated with alkaline phosphatase and then ligated with the multiple cloning site obtained by hybridization of the following 2 oligonucleotides: JCA088 (39 mer) (SEQ ID No. 27) 5′ CTAGTCCAGCAAGGTGTCGACGGATCGATATCGGGCCCA 3′ JCA089 (39 mer) (SEQ ID No. 28) 5′ CTAGTGGGCCCGATATCGATCCGTCGACACCTTGCTGGA 3′ to give plasmid pPB200′ (4135 bp) ( FIG. 10 ).
- Plasmid pCMVB (Clontech Ref. 6177-1) was digested with EcoRI and NotI to isolate an 818-bp EcoRI-NotI fragment containing the promoter region of the human cytomegalovirus immediate-early gene (fragment A).
- RNA of the rabies virus ERA strain was extracted and purified from a culture of rabies virus-infected Vero cells. An RT-PCR reaction was then carried out (see Example 7) with the genomic RNA of the rabies virus (strain ERA) and with the following oligonucleotides: JCA090 (31 mer) (SEQ ID No. 29) 5′ TTGCGGCCGCATGGTTCCTCAGGCTCTCCTG 3′ JCA091 (31 mer) (SEQ ID No.
- a PCR reaction was carried out with plasmid pCMVB and with the following oligonucleotides: PB088 (30 mer) (SEQ ID No. 23) 5′ TTGGGTACCGCCTCGACTCTAGGCGGCCGC 3′ PB089 (32 mer) (SEQ ID No. 24) 5′ TTGGGTACCGGATCCGAAAAAACCTCCCACAC 3′ to obtain a 244-bp PCR fragment containing the polyadenylation signal of the SV40 virus early gene. This fragment was digested with KpnI to isolate a 233-bp KpnI-KpnI fragment.
- Plasmid pPB212 was digested with EcoRV and SalI to isolate a 2664-bp EcoRV-SalI fragment containing the cassette for the expression of the rabies virus G gene. This fragment was then ligated with plasmid pPB200′ (see above), previously digested with EcoRV and SalI, to give plasmid pPB215 (6790 bp) ( FIG. 12 ).
- Plasmid pPB208 (Example 7.1.) was digested with SmaI and ApaI to isolate a 2909-bp SmaI-ApaI fragment containing the cassette for the expression of the CDV HA gene. This fragment was then ligated with plasmid pPB202 (Example 4), previously digested with EcoRV and ApaI, to give plasmid pPB216 (6291 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF5 site.
- Plasmid pPB208 (Example 7.1.) was digested with ApaI and ClaI to isolate a 2920-bp fragment containing the cassette for the expression of the CDV HA gene. This fragment was ligated with plasmid pPB204 (Example 5), previously digested with ApaI and ClaI, to give plasmid pPB217 (6316 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the CHV TK site.
- Plasmid pPB208 (Example 7.1.) was digested with ApaI and ClaI to isolate a 2920-bp fragment containing the cassette for the expression of the CDV HA gene. This fragment was ligated with plasmid pPB206 (Example 6), previously digested with ApaI and ClaI, to give plasmid pPB218 (6462 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the site situated between the CHV ORF19 and CHV ORF22 genes.
- Plasmid pPB213 (see Example 8) was linearized by digestion with HindIII, extracted with a phenol-chloroform mixture, precipitated with absolute ethanol and then taken up in sterile water.
- the cells were then left in culture for 24 hours at +37° C. After 24 hours to 48 hours of culture, 1 ml of culture supernatant was harvested, and several dilutions of this supernatant were used to infect other MDCK cells (cultured in Petri dishes (Corning 4.5 cm in diameter)) so as to obtain isolated plaques, each dish being infected with 1 ml of a dilution of the initial supernatant. After contact for 1 hour at 37° C., the infection medium was removed and replaced by 5 ml of MEM medium containing 1% of agarose, kept supercooled at 42° C. When the agarose had solidified, the dishes were incubated for 48 hours at 37° C. in a CO 2 incubator until plaques were seen.
- the agarose layer was then removed, and a transfer of the viral plaques was carried out onto a sterile nitrocellulose membrane of the same diameter as the Petri dish used for culturing. This membrane was itself transferred onto another nitrocellulose membrane so as to obtain an inverted “copy” of the first transfer.
- the plaques transferred onto this second copy were then hybridized, according to the standard techniques known to a person skilled in the art, with a 1842-bp NotI-NotI fragment of the CDV HA gene, obtained by digestion of plasmid pPB208 (Example 7.1.), labelled with digoxigenin (DNA Labelling kit, Boehringer Mannheim, CAT # 1175033).
- the nitrocellulose membrane was placed in contact with an autoradiographic film.
- the images of positive hybridization on this membrane indicated which plaques were the ones which contained recombinant CHV viruses which had inserted the CDV HA cassette.
- the plaques corresponding to these positive plaques were cut out under sterile conditions from the first nitrocellulose membrane, placed in an Eppendorf tube containing 0.5 ml of MEM medium and sonicated to release the virions from the membrane.
- the medium contained in the Eppendorf tube was then diluted in MEM medium, and the dilutions thereby obtained were used to infect further cultures of MDCK cells.
- a 100% pure recombinant virus containing the HCMV-IE/CDV HA/polyA cassette inserted into the ORF3 site was thereby isolated after 3 cycles of purification, and was called vCHV01.
- the homology of the recombination was verified by PCR using oligonucleotides situated on each side of the insertion site.
- Example 14 the construction of different recombinant CHV viruses is carried out using the donor plasmids described in Examples 9 to 13.
- the recombinant viruses obtained in Examples 14 and 15 are cultured on MDCK cells. Harvesting of the recombinant virus takes place when the cytopathic effect is complete. The lysed cells and the culture supernatant are harvested. After clarification of the cell lysate to remove cell debris, the viral solution is titrated. The viral solution is then diluted in a stabilizing solution for lyophilization, distributed on the basis of one vaccinal dose (10 2 CCID50 to 10 7 CCID50) per vial and lastly lyophilized. The viral solution can then be frozen if necessary.
- the vaccine obtained according to the invention is redissolved or thawed, and then administered via the parenteral or mucosal route, but preferably via the mucosal, in particular the oral and/or nasal, route.
- the vaccinal dose will preferably be between 10 2 CCID50 and 10 7 CCID50.
- the dose for the parenteral route will be between 10 4 CCID50 and 10 7 CCID50, and for the oral and/or nasal route, between 10 2 CCID50 and 10 5 CCID50.
- the vaccine is effective in general after a single administration via the oral and/or nasal route. However, repeated administrations may be necessary.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Disclosed and claimed is a recombinant canine herpes virus (CHV). The recombinant CHV includes and expresses at least one heterologous nucleotide sequence encoding an antigen. The antigen can be canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, or Borrelia burgdorferi OspB. The at least one heterologous nucleotide sequence can be in at least one insertion site selected from the group consisting of ORF3 (SEQ ID NO:4), ORF5 (SEQ ID NO:5), the thymidine kinase gene, and the intergenic region corresponding to genes coding for the large subunit and the small subunit. Immunological or vaccine compositions as well as methods for inducing an immunological response are also disclosed and claimed.
Description
- The present invention relates to vaccines, preferably for dogs, produced from recombinant canine herpesviruses, and to the methods for obtaining and preparing these recombinant viruses. The present invention relates more especially to recombinant canine herpesviruses comprising an expression cassette for one or more foreign gene(s).
- Canine herpesvirosis is caused by the canine herpesvirus (CHV). The canine herpesvirus (CHV) is classified in the Alphaherpesvirinae family. This herpesvirus is a major pathogen for neonatal puppies. Canine herpesvirosis manifests itself chiefly in a haemorrhagic disease in puppies, and in a benign disease of the upper respiratory apparatus in adult dogs. There are at present no vaccines for protecting puppies against canine herpesvirosis.
- Moreover, domestic dogs are exposed to numerous other diseases, and the development of a vaccinal vector capable of expressing different antigens of canine pathogenic agents would enable the efficacy of vaccination programmes to be simplified and improved, especially for puppies in breeding kennels. Among pathogenic agents of importance for dogs, the Carre's disease virus, the Rubarth's hepatitis virus, the rabies virus, the canine parvovirosis virus, the canine coronavirus, the parainfluenza virus type 2, Bordetella bronchiseptica, Borrelia burgdorferi, Leptospira spp. and Leishmania infantum may be mentioned.
- Little is known about the CHV virus genome. The genomic organization of this virus was published only recently (Rémond M. et al. J. Gen. Virol. 1996. 77. 37-48), and the genes for the three major glycoproteins gB, gC and gD, as well as a gene designated CHV ORF2, have been described (K. Limbach et al. J. Gen. Virol. 1994. 75. 2029-2039).
- Following their work on CHV, the inventors have succeeded in determining several regions which are non-essential for replication in vitro, which have proved useful for the construction of recombinant CHV viruses. The inventors are hence in a position to put forward for the first time the CHV virus as a vaccination vector for dogs. It was found that the vaccinal vectors according to the invention had particular advantages for the vaccination of dogs. In effect, the canine herpesvirus is very species-specific and possesses a large genome containing several potential insertion sites and permitting the simultaneous insertion of several expression cassettes for foreign genes. This affords the possibility of vaccinating dogs at the same time against different canine pathogenic agents using a single recombinant virus.
- The main objective of the invention is to provide a vaccinal vector permitting the expression of immunogens of canine pathogens for the purpose of protecting dogs against the main canine infectious diseases.
- Another objective of the invention is to provide such a vector permitting the vaccination of dogs, and especially puppies having maternal antibodies, via the mucosal, in particular the oral, nasal or conjunctival, route.
- Yet another objective of the invention is to provide such a vector which permits vaccination at the same time against herpesvirosis in puppies.
- Hence the subject of the present invention is a recombinant live vaccine using as vector a canine herpesvirus comprising and expressing at least one nucleotide sequence coding for a polypeptide, this sequence being inserted into a site which is non-essential for replication in vitro.
- The inventors have isolated and analysed a genomic fragment of the CHV virus, on which they have characterized 5 open reading frames (ORF1 to ORF5), among which two (ORF3 and ORF5) have proved to be non-essential for replication in vitro. Moreover, the inventors have found that other regions of the CHV genome could also be used to insert foreign genes. These insertion sites are: thymidine kinase gene (CHV TK ORF) (Rémond M. et al. Virus Research. 1995. 39. 341-354.) and sequence situated between the CHV ORF19 and the CHV ORF22 (Rémond M. et al. J. Gen. Virol. 1996. 76. 37-48). These sites are described more precisely in the examples of the present invention.
- Preferably, the inserted sequence codes for an antigenic polypeptide, and preferentially for an antigenic polypeptide of a canine pathogenic agent. It is also possible to insert the sequences coding for immunomodulatory proteins such as cytokines. According to an advantageous variant, it is possible to use in combination a sequence coding for a cytokine, or the like, and a sequence coding for an antigen. If need be, several cytokine sequences can be used in combination with one another, optionally in combination with one or more sequences coding for antigens.
- The insertion into the sites is carried out by simple insertion (without deletion), or after partial or total deletion of the ORF or ORFs used as insertion sites.
- As a parent virus for the construction of recombinant CHV viruses, it is possible to use, in particular, the CHV strain F205 which was isolated by L. Carmichael (Proc. Soc. Exp. Biol. Med. 1965. 120. 644-650).
- For the expression of foreign genes inserted into the CHV genome according to the present invention, it will be preferable to use a strong eukaryotic promoter such as, preferentially, a cytomegalovirus (CMV) immediate-early (IE) promoter. CMV IE promoter is understood to mean, in particular, a fragment such as is given in the examples, as well as the subfragments thereof retaining the same promoter activity. The CMV IE promoter can be the human (HCMV IE) promoter or the murine (MCMV IE) promoter, or alternatively a CMV IE promoter of another origin, for example rat, guinea pig or porcine CMV.
- At least two nucleotide sequences may be inserted into one site under the control of different promoters. The latter may be, in particular, CMV IE promoters of different origins.
- According to an advantageous development of the invention, another promoter is used in combination with the CMV IE promoter in such a way that the two promoters have their 5′ ends adjacent and that the transcriptions initiated from these two promoters take place in opposite directions. This particular arrangement enables two nucleotide sequences to be inserted into the same site, one under the control of the CMV IE promoter and the other under that of the promoter used in combination with it. This construction is noteworthy from the fact that the presence of the CMV IE promoter, and in particular of its enhancer portion, can activate the transcription induced by the promoter used in combination. As a promoter used in combination, there may be mentioned, for example, a CMV promoter of different species from the first promoter. It is also possible to envisage other promoters, such as the Marek's disease virus (MDV) RNA1.8 promoter (G. Bradley et al. J. Virol. 1989. 63. 2534-2542).
- The nucleotide sequence inserted into the CHV vector in order to be expressed can be any sequence coding for an antigenic polypeptide of a canine pathogenic agent capable, when expressed under the favourable conditions obtained by the invention, of bringing about an immunization leading to an effective protection of the vaccinated animal against the pathogenic agent. The nucleotide sequences coding for the antigens of interest for a given disease, in particular the viral, bacterial or parasitic diseases mentioned above, may hence be inserted under the conditions described by the present invention.
- The typical case of the invention is the insertion of at least one nucleotide sequence coding appropriately for a polypeptide of the Carré's disease virus (canine distemper virus=CDV), and preferably for the CDV polypeptide HA (Sidhu M. et al., Virology. 1993. 193. 66-72) or for the CDV polypeptide F (Barrett T. et al. Virus Research. 1987. 8. 373-386). It is also possible to insert both of these genes together into the CHV vector. A recombinant live vaccine bringing about protection against Carré's disease is thereby obtained.
- Other preferred cases of the invention are the insertion of nucleotide sequences coding for antigens or fragments of antigens of the rabies virus, especially the G gene (Patents FR-A-2,515,685 and EP-A-162,757), of the canine parvovirosis virus (VP2 gene) (Parrish C. et al. J. Virol. 1991. 65. 6544-6552) or of the parainfluenza virus type 2 (HA and/or F genes). It is also possible to insert sequences coding for Borrelia burgdorferi antigens, especially the genes coding for the OspA and OspB antigens (Bergström S. et al. Mol. Microbiol. 1989. 3. 479-486).
- A typical case of the invention is a vaccine comprising a nucleotide sequence coding for an antigen of the Carré's disease virus under the control of CMV IE, and a nucleotide sequence coding for an antigen of another canine viral disease, in particular the ones mentioned above, under the control of the other promoter.
- Naturally, the heterologous sequences and their associated promoters may be inserted more conventionally in tandem into the insertion locus, that is to say according to the same transcription direction.
- The expression of several heterologous genes inserted into the insertion locus can also be possible by insertion of a sequence known as an “IRES” (internal ribosome entry site) originating, in particular, from a picornavirus such as the swine vesicular disease virus (SVDV; B.-F. Chen et al., J. Virology, 1993, 67, 2142-2148), the encephalomyocarditis virus (EMCV; R. J. Kaufman et al., Nucleic Acids Research, 1991, 19, 4485-4490) or the aphthous fever virus (FMDV; N. Luz and E. Beck, J. Virology, 1991, 65, 6486-6494), or alternatively of another origin. The content of these three papers is incorporated by reference. The cassette for expression of two genes would hence have the following minimum structure: promoter—
gene 1—IRES—gene 2—polyadenylation signal. The recombinant live vaccine according to the invention may hence comprise, inserted into the insertion locus, an expression cassette comprising in succession a promoter, two or more genes separated in pairs by an IRES, and a polyadenylation signal. - In addition to the insertion into the locus according to the invention, it is possible to carry out one or more other insertions, one or more mutations or one or more deletions elsewhere in the genome. In all cases, insertion into a locus other than the one described in the invention enables other genes to be expressed.
- The use of the recombinant viruses according to the invention enables dogs to be protected against one or more of the diseases mentioned above, and at the same time against canine herpesvirosis.
- The subject of the present invention is also a polyvalent vaccine formula comprising, as a mixture or to be mixed, at least two recombinant live vaccines as defined above, these vaccines comprising different inserted sequences isolated, in particular, from different pathogens. These vaccine formulae contain dosages and/or vehicles which are suited to the administration route.
- The subject of the present invention is also CHV viruses modified in at least one of the sites indicated.
- Its subject is also a method of vaccination, especially of dogs, in which an effective amount of a vaccine as defined above is administered via any parenteral or mucosal route, but preferably via the mucosal, in particular the oral and/or nasal, route. The vaccinal dose will preferably be between 102 CCID50 and 107 CCID50. Preferably, the dose for the parenteral route will be between 104 CCID50 and 107 CCID50, and for the oral and/or nasal route, between 102 CCID50 and 105 CCID50. As defined, the vaccine is effective in general after a single administration via the oral and/or nasal route. However, repeated administrations may be necessary.
- The subject of the present invention is also the DNA fragments comprising all or part of the sequence defined by
positions 1 to 6216 on SEQ ID No. 1 (FIG. 1 ), in particular all or part of the ORF3 site defined and/or of the flanking sequences located upstream and downstream of this site, which fragments will be useful as flanking arms for the techniques of homologous recombination with the genome of the CHV virus chosen as parent virus. Naturally, the invention also relates to the variants of these fragments which correspond to the equivalent sequences of the other strains of CHV. The expert is entirely free to choose the regions serving as flanking arms in connection with the type of insertion (with or without deletion) or of deletion (partial or total) chosen. Generally speaking, the flanking arms may thus have from 100 to 800 base pairs, but can be larger if necessary. - A further subject of the invention is a method of preparation of the vectors and vaccines according to the invention, as emerges from the description of the vaccines, by insertion of genes of interest into the insertion site.
- The invention will now be described in greater detail by means of non-limiting examples of implementation, taken with reference to the drawing, wherein:
-
FIG. 1 : Sequence of the CHV region (6216 base pairs) and translation of the different open reading frames (ORFs) present in this sequence (ORF1 to ORF5). -
FIG. 2 : Plasmid pPB200 (donor plasmid for the insertion of expression cassettes into the CHV ORF3 site). -
FIG. 3 : Construction of the plasmid pP3202 (donor plasmid for the insertion of expression cassettes into the CHV ORF5 site). -
FIG. 4 : Construction of the plasmid pPB204 (donor plasmid for the insertion of expression cassettes into the CHV TK site). -
FIG. 5 : Construction of the plasmid pPB206 (donor plasmid for the insertion of expression cassettes into the site situated between the CHV ORF19 and CHV ORF22 genes). -
FIG. 6 : Construction of the plasmid pPB208 (expression cassette for the CDV HA gene). -
FIG. 7 : Construction of the plasmid pPB210 (expression cassette for the CDV F gene). -
FIG. 8 : Construction of the plasmid pPB213 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF3 site). -
FIG. 9 : Construction of the plasmid pPB214 (donor plasmid for the insertion of the cassette for the expression of the CDV F gene into the CHV ORF3 site). -
FIG. 10 : Plasmid pPB200′ -
FIG. 11 : Construction of the plasmid pPB212 (cassette for the expression of the rabies virus G gene). -
FIG. 12 : Construction of the plasmid pPB125 (donor plasmid for the insertion of the cassette for the expression of the rabies virus G gene into the CHV ORF3 site). -
FIG. 13 : Construction of the plasmid pPB216 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF5 site). -
FIG. 14 : Construction of the plasmid pPB217 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the CHV TK site). -
FIG. 15 : Construction of the plasmid pPB218 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the site situated between the CHV ORF19 and CHV ORF22 genes). - SEQ ID sequence listing for the constructions in the insertion sites of the CHV vector:
- SEQ ID No. 1 Complete sequence of the CHV ORF1→ORF5 region depicted in
FIG. 1 - SEQ ID No. 2 ORF1 amino acid sequence of
FIG. 1 - SEQ ID No. 3 ORF2 amino acid sequence of
FIG. 1 - SEQ ID No. 4 ORF3 amino acid sequence of
FIG. 1 - SEQ ID No. 5 ORF4 amino acid sequence of
FIG. 1 - SEQ ID No. 6 (Partial) ORF5 amino acid sequence of
FIG. 1 - SEQ ID No. 7 oligonucleotide JCA070
- SEQ ID No. 8 oligonucleotide JCA071
- SEQ ID No. 9 oligonucleotide JCA072
- SEQ ID No. 10 Oligonucleotide JCA073
- SEQ ID No. 11 Oligonucleotide JCA074
- SEQ ID No. 12 Oligonucleotide JCA075
- SEQ ID No. 13 Oligonucleotide JCA076
- SEQ ID No. 14 Oligonucleotide JCA077
- SEQ ID No. 15 Oligonucleotide JCA078
- SEQ ID No. 16 Oligonucleotide JCA079
- SEQ ID No. 17 Oligonucleotide JCA080
- SEQ ID No. 18 Oligonucleotide JCA081
- SEQ ID No. 19 Oligonucleotide JCA082
- SEQ ID No. 20 Oligonuc JCA083
- SEQ ID No. 21 Oligonucleotide JCA084
- SEQ ID No. 22 Oligonucleotide JCA085
- SEQ ID No. 23 Oligonucleotide PB088
- SEQ ID No. 24 Oligonucleotide PB089
- SEQ ID No. 25 Oligonucleotide JCA086
- SEQ ID No. 26 Oligonucleotide JCA087
- SEQ ID No. 27 Oligonucleotide JCA088
- SEQ ID No. 28 Oligonucleotide JCA089
- SEQ ID No. 29 Oligonucleotide JCA090
- SEQ ID No. 30 Oligonucleotide JCA091
- All the constructions of plasmids were carried out using the standard techniques of molecular biology described by Sambrook J. et al. (Molecular Cloning: A Laboratory Manual. 2nd Edition. Cold Spring Harbor Laboratory. Cold Spring Harbor. N.Y. 1989). All the restriction fragments used for the present invention were isolated using the “Geneclean” kit (BIO 101 Inc. La Jolla, Calif.).
- The virus used as parent virus is the canine herpesvirus strain F205 (also known as the Carmichael strain). This strain was obtained from Dr. L. Carmichael (Cornell University, NY), who isolated it and described its biological characteristics (Proc. Soc. Exp. Biol. Med. 1965. 120. 644-650). The conditions of culture of this virus are as follows: MDCK (Madin-Darby canine kidney ATCC CCL34) cells cultured in Eagle's minimum essential medium (MEM medium) are inoculated with the CHV strain F205 using a multiplicity of infection of 1. The infected cells are then incubated at 37° C. for approximately 36 hours until a complete cytopathic effect is seen.
- Extraction of Canine Herpesvirus DNA
- After culture, the supernatant and the lysed cells are harvested, and the whole of the viral suspension is centrifuged at 1000 g for 10 minutes at +4° C. to remove cell debris. The viral particles are then harvested by ultracentrifugation at 400,000 g for 1 hour at +4° C. The pellet is taken up in a minimum volume of buffer (10 mM Tris, 1 mM EDTA). This concentrated viral suspension is treated with proteinase K (100 μg/ml final) in the presence of sodium dodecyl sulphate (SDS) (0.5% final) for 2 hours at 37° C. The viral DNA is then extracted with a phenol/chloroform mixture and thereafter precipitated with 2 volumes of absolute ethanol. After one night at −20° C., the precipitated DNA is centrifuged at 10,000 g for 15 minutes at +4° C. The DNA pellet is dried and then taken up in a minimum volume of sterile ultrapure water.
- Cloning and Characterization of the CHV ORF1-ORF5 Region
- The purified genomic DNA of the CHV virus strain F205 was digested with the restriction enzymes ScaI and XhoI, and the approximately 6200-bp ScaI-XhoI fragment was cloned into the vector pBlueScript SKII+ (Stratagene Ref. 212205), previously digested with ScaI and XhoI, to give the plasmid pPB154.
- The XhoI-ScaI fragment cloned into plasmid pPB154 was sequenced completely on both strands to generate the 6216-bp sequence of
FIG. 1 (SEQ ID No. 1). - Several open reading frames larger than 65 amino acids in size were identified on this sequence (
FIG. 1 ): - The first reading frame (ORF1) (positions 1353-157) occurs on the complementary strand and codes for a polypeptide of 398 amino acids (SEQ ID No. 2).
- The second reading frame (ORF2) (positions 1708-2970) codes for a polypeptide of 420 amino acids (SEQ ID No. 3).
- The third reading frame (ORF3) (positions 3040-4242) codes for a polypeptide of 400 amino acids (SEQ ID No. 4).
- The fourth reading frame (ORF4) (positions 4374-5753) codes for a polypeptide of 459 amino acids (SEQ ID No. 5).
- The fifth reading frame (ORF5) (positions 5872-6216) is incomplete and codes for a truncated protein of 115 amino acids (SEQ ID No. 6).
- The different open reading frames are collated in the table below:
Open reading Beginning-End Size in amino frame (positions in Figure 1) acids ORF 1 1353-157 398 aa ORF 2 1708-2970 420 aa ORF 3 3040-4242 400 aa ORF 4 4374-5753 459 aa ORF 5 5872-6216 115 aa - Construction of Plasmid pPB200 for the Insertion of Expression Cassettes Into the CIV ORF3 Site (
FIG. 2 ) - Plasmid pPB154 (9121 bp) (Example 2) was digested with HindIII and SpeI to isolate the 620-bp HindIII-SpeI fragment (fragment A). Plasmid pPB154 was digested with EcoRI and SpeI to isolate the 659-bp EcoRI-SpeI fragment (fragment B). The fragments A and B were ligated together with the vector pGEM4Z (Promega Ref. P2161), previously digested with EcoRI and HindIII, to give the plasmid pPB199 (4096 bp). Plasmid pPB199 was then digested with SpeI, treated with alkaline phosphatase and then ligated with the multiple cloning site obtained by hybridization of the following 2 oligonucleotides:
JCA070 (33 mer) (SEQ ID No. 7) 5′ CTAGTCCAGCAAGGTGGATCGATATCGGGCCCA 3′JCA071 (33 mer) (SEQ ID No. 8) 5′ CTAGTGGGCCCGATATCGATCCACCTTGCTGGA 3′
to give plasmid pPB200 (4129 bp). - Construction of Plasmid pPB202 for the Insertion of Expression Cassettes Into the CHV ORF5 Site (
FIG. 3 ) - The sequence of the CHV ORF5 gene was published recently (Limbach K. et al. J. Gen. Virol. 1994. 75. 2029-2039). A PCR reaction was carried out with the genomic DNA of the CHV virus strain F205 (Example 1) and with the following oligonucleotides:
JCA072 (22 mer) (SEQ ID No. 9) 5′ CAGCTTTATGTTTTTATTGTTC 3′JCA073 (29 mer) (SEQ ID No. 10) 5′ AAAGAATTCTACAACTGTTTAATAAAGAC 3′ - to obtain a 751-bp PCR fragment containing the complete CHV ORF2 gene. This fragment was digested with BGlII and EcoRI to isolate a 709-bp BglII-EcoRI fragment. This fragment was ligated with the vector pGEM4Z (Promega Ref. P2161), previously digested with EcoRI and BamhI, to give the plasmid pPB201 (3559 bp). Plasmid pPB201 was then digested with ScaI and PvuII and thereafter ligated with a multiple cloning site obtained by hybridization of the following 2 oligonucleotides:
JCA074 (36 mer) (SEQ ID No. 11) 5′ ACTCCAGCTACATGGGATATCGGGCCCATCGATCAG 3′JCA075 (36 mer) (SEQ ID No. 12) 5′ CTGATCGATGGGCCCGATATCCCATGTAGCTGGAGT 3′
to give plasmid pPB202 (3395 bp). - Construction of Plasmid pPB204 for the Insertion of Expression Cassettes Into the CHV TK Site (
FIG. 4 ) - The sequence of the CHV thymidine kinase (TK) gene was published recently (Rémond M. et al. Virus Research. 1995. 39. 341-354). A PCR reaction was carried out with the genomic DNA of the CHV virus strain F205 (Example 1) and with the following oligonucleotides:
JCA076 (35 mer) (SEQ ID No. 13) 5′ AGCGTTAACCTCAAAAGCCAAATTTACACTTCCCG 3′JCA077 (38 mer) (SEQ ID No. 14) 5′ CCCAAGCTTTTCTAAAGCCCATTTATAAATAATAAATG 3′
to obtain a 1030-bp PCR fragment containing the thymidine kinase (TK) gene. This fragment was digested with HpaI and HindIII to isolate a 1019-bp HpaI-HindIII fragment. This fragment was ligated with the vector pSP73 (Promega Ref. P2221), previously digested with EcoRV and HindIII, to give the plasmid pPB203 (3423 bp). - Plasmid pPB203 was then digested with EcoRI and StyI and thereafter ligated with a multiple cloning site obtained by hybridization of the following 2 oligonucleotides:
JCA078 (36 mer) (SEQ ID No. 15) 5′ AATTCCCAGCTACATGGGATATCGGGCCCATCGATC 3′JCA079 (36 mer) (SEQ ID No. 16) 5′ CAAGGATCGATGGGCCCGATATCCCATGTAGCTGGG 3′
to give plasmid pPB204 (3399 bp). - Construction of Plasmid pPB206 for the Insertion of Expression Cassettes Into the Site Situated Between the CHV ORF19 and ORF22 Genes (
FIG. 5 ) - The sequence of the intergenic region corresponding to the natural deletion of the genes coding for the large subunit (“RR1” gene) and for the small subunit (“RR2” gene) of ribonucleotide reductase was published recently (Rémond M. et al. J. Gen. Virol. 1996, 77. 37-48). According to the nomenclature used by Rémond et al., the deletion of these two genes occurs between the open reading frames designated CHV “orf19” and CHV “orf22” [designated herein ORF19 and ORF 22, respectively]. A PCR reaction was carried out with the genomic DNA of the CHV virus strain F205 (Example 1) and with the following oligonucleotides:
JCA080 (36 mer) (SEQ ID No. 17) 5′ GGAGATCTAGTAAATTAAATAGTAATTCATTTAATG 3′JCA081 (33 mer) (SEQ ID No. 18) 5′ CAGTCGCGAAGATGAAAATAAAATCCATCGAAG 3′ - to obtain a 720-bp PCR fragment containing the intergenic region corresponding to the natural deletion of the CHV ORF19 and ORF22 genes. This fragment was digested with SpeI and NruI to isolate a 709-bp SpeI-NruI fragment. This fragment was ligated with the vector pGEM4Z (Promega Ref. P2161), previously digested with SmaI and XbaI, to give the plasmid pPB205 (3572 bp). Plasmid pPB205 was then digested with MfeI and thereafter partially digested with SspI in order to isolate the 3512-bp MfeI-SspI fragment. This fragment was then ligated with a multiple cloning site obtained by hybridization of the following 2 oligonucleotides:
JCA082 (38 mer) (SEQ ID No. 19) 5′ AATTGGCAGCTACATGGGATATCGGGCCCATCGATAAT 3′JCA083 (34 mer) (SEQ ID No. 20) 5′ ATTATCGATGGGCCCGATATCGGATGTAGCTGGC 3′
to give plasmid pPB206 (3548 bp). - Isolation of the Genomic RNA of the CDV Strain Onderstepoort and Cloning of the Complementary DNA Coding for the HA and F Genes
- The CDV strain Onderstepoort (Mitchell W. et al. J. Virol. Meth. 1987. 18. 121-131) was cultured on MDCK (Madin-Darby canine kidney) cells in DMEM medium (Gibco). After purification of the virus, the genomic viral RNA was isolated using the guanidinium thiocyanate/phenol-chloroform extraction technique (Chomczynski P. and Sacchi N., Anal. Biochem. 1987. 162. 156-159). Specific oligonucleotides (containing restriction sites at their 5′ ends to facilitate the cloning of the amplified fragments) were synthesized in such a way as to cover completely the coding regions of the genes which were to be amplified (HA and F genes, respectively). The reverse transcription (RT) reaction and polymerase chain amplification (PCR) were performed according to the standard techniques (Sambrook J. et al. 1989). Each RT-PCR reaction was carried out with a pair of specific amplimers and taking as template the extracted viral genomic RNA. The amplified complementary DNA was extracted with phenol/chloroform/isoamyl alcohol (25:24:1) before being digested with the restriction enzymes and cloned into the appropriate vector.
- 7.1. Construction of the CDV HA Expression Cassette (pPB208) (
FIG. 6 ) - The plasmid pCMVB (Clontech Ref. 6177-1) was digested with EcoRI and NotI to isolate an 818-bp EcoRI-NotI fragment containing the promoter region of the human cytomegalovirus immediate-early gene (fragment A).
- An RT-PCR reaction was carried out with the genomic RNA of the CDV virus (strain Onderstepoort) and with the following oligonucleotides:
JCA084 (32 mer) (SEQ ID No. 21) 5′ TTGCGGCCGCATGCTCCCCTACCAAGACAAGG 3′JCA085 (28 mer) (SEQ ID No. 22) 5′ TTGGTACCTTAACGGTTACATGAGAATC 3′
to obtain a 1837-bp PCR fragment containing the CDV HA gene. This fragment was digested with NotI and KpnI to isolate a 1826-bp NotI-KpnI fragment (fragment B). - The fragments A and B were ligated together with the vector pGEM-7Zf+ (Promega Cat # P2251), previously digested with EcoRI and KpnI, to give the plasmid pPB207 (5634 bp).
- A PCR reaction was carried out with plasmid pCMVB and with the following oligonucleotides:
PB088 (30 mer) (SEQ ID No. 23) 5′ TTGGGTACCGCCTCGACTCTAGGCGGCCGC 3′PB089 (32 mer) (SEQ ID No. 24) 5′ TTGGGTACCGGATCCGAAAAAACCTCCCACAC 3′
to obtain a 244-bp PCR fragment containing the polyadenylation signal of the SV40 virus early gene. This fragment was digested with KpnI to isolate a 233-bp KpnI-KpnI fragment. This fragment was then ligated with plasmid pPB207, previously digested with KpnI, to give plasmid pPB208 (5867 bp).
7.2. Construction of the CDV F Expression Cassette (pPB210) (FIG. 7 ) - Plasmid PCMVB (Clontech Ref. 6177-1) was digested with EcoRI and NotI to isolate an 818-bp EcoRI-NotI fragment containing the promoter region of the human cytomegalovirus immediate-early gene (fragment A).
- An RT-PCR reaction was carried out with the genomic RNA of the CDV virus (strain Onderstepoort) and with the following oligonucleotides:
JCA086 (34 mer) (SEQ ID No. 25) 5′ TTGCGGCCGCATGCACAGGGGAATCCCCAAAAGC 3′JCA087 (28 mer) (SEQ ID No. 26) 5′ TTGGTACCTCAGAGTGATCTCACATAGG 3′
to obtain a 2011-bp PCR fragment containing the CDV F gene. This fragment was digested with NotI and KpnI to isolate a 2000-bp NotI-KpnI fragment (fragment B). The fragments A and B were ligated together with the vector pGEM-7Zf+ (Promega Ref. P2251), previously digested with EcoRI and KpnI, to give the plasmid pPB209 (5808 bp). - A PCR reaction was carried out with plasmid pCMVB and with the following oligonucleotides:
PB088 (30 mer) (SEQ ID No. 23) 5′ TTGGGTACCGCCTCGACTCTAGGCGGCCGC 3′PB089 (32 mer) (SEQ ID No. 24) 5′ TTGGGTACCGGATCCGAAAAAACCTCCCACAC 3′
to obtain a 244-bp PCR fragment containing the polyadenylation signal of the SV40 virus early gene. This fragment was digested with KpnI to isolate a 233-bp KpnI-KpnI fragment. This fragment was then ligated with plasmid pPB209, previously digested with KpnI, to give plasmid pPB210 (6041 bp). - Construction of the Donor Plasmid pPB213 for the Insertion of the CDV HA Expression Cassette Into the CHV ORF3 Site (
FIG. 8 ) - Plasmid pPB208 (Example 7.1.) was digested with ApaI and ClaI to isolate a 2920-bp ApaI-ClaI fragment containing the cassette for the expression of the CDV virus HA gene. This fragment was then ligated with plasmid pPB200 (Example 3), previously digested with ApaI and ClaI, to give plasmid pPB213 (7043 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF3 site.
- Construction of the Donor Plasmid pPB214 for the Insertion of the CDV F Expression Cassette Into the CHV ORF3 Site (
FIG. 9 ) - Plasmid pPB210 (Example 7.2.) was digested with ApaI and ClaI to isolate a 3100-bp ApaI-ClaI fragment containing the cassette for the expression of the CDV virus F gene. This fragment was then ligated with plasmid pPB200 (Example 3), previously digested with ApaI and ClaI, to give plasmid pPB214 (7217 bp). This plasmid permits the insertion of the cassette for the expression of the CDV F gene into the CHV ORF3 site.
- Construction of the Donor Plasmid pPB215 for the Insertion of the Cassette for the Expression of the Rabies Virus G Gene Into the CHV ORF3 Site (
FIGS. 10, 11 and 12) - Plasmid pPB199 (Example 3) was digested with SpeI, treated with alkaline phosphatase and then ligated with the multiple cloning site obtained by hybridization of the following 2 oligonucleotides:
JCA088 (39 mer) (SEQ ID No. 27) 5′ CTAGTCCAGCAAGGTGTCGACGGATCGATATCGGGCCCA 3′JCA089 (39 mer) (SEQ ID No. 28) 5′ CTAGTGGGCCCGATATCGATCCGTCGACACCTTGCTGGA 3′
to give plasmid pPB200′ (4135 bp) (FIG. 10 ). - Plasmid pCMVB (Clontech Ref. 6177-1) was digested with EcoRI and NotI to isolate an 818-bp EcoRI-NotI fragment containing the promoter region of the human cytomegalovirus immediate-early gene (fragment A).
- According to the technical procedures already described for the CDV virus (Example 7), the RNA of the rabies virus ERA strain was extracted and purified from a culture of rabies virus-infected Vero cells. An RT-PCR reaction was then carried out (see Example 7) with the genomic RNA of the rabies virus (strain ERA) and with the following oligonucleotides:
JCA090 (31 mer) (SEQ ID No. 29) 5′ TTGCGGCCGCATGGTTCCTCAGGCTCTCCTG 3′JCA091 (31 mer) (SEQ ID No. 30) 5′ TTGGTACCTCACAGTCTGGTCTCACCCCCAC 3′
to obtain a 1597-bp PCR fragment containing the rabies virus G gene (Patents FR-A-2,515,685 and EP-A-162,757). This fragment was digested with NotI and KpnI to isolate a 1586-bp NotI-KpnI fragment (fragment B). The fragments A and B were ligated together with the vector pSP73 (Promega Ref. P2221), previously digested with EcoRI and KpnI, to give the plasmid pPB211 (4852 bp). - A PCR reaction was carried out with plasmid pCMVB and with the following oligonucleotides:
PB088 (30 mer) (SEQ ID No. 23) 5′ TTGGGTACCGCCTCGACTCTAGGCGGCCGC 3′PB089 (32 mer) (SEQ ID No. 24) 5′ TTGGGTACCGGATCCGAAAAAACCTCCCACAC 3′
to obtain a 244-bp PCR fragment containing the polyadenylation signal of the SV40 virus early gene. This fragment was digested with KpnI to isolate a 233-bp KpnI-KpnI fragment. This fragment was then ligated with plasmid pPB211, previously digested with KpnI, to give plasmid pPB212 (5085 bp) (FIG. 11 ). Plasmid pPB212 was digested with EcoRV and SalI to isolate a 2664-bp EcoRV-SalI fragment containing the cassette for the expression of the rabies virus G gene. This fragment was then ligated with plasmid pPB200′ (see above), previously digested with EcoRV and SalI, to give plasmid pPB215 (6790 bp) (FIG. 12 ). - Construction of the Donor Plasmid pPB216 for the Insertion of the CDV HA Expression Cassette Into the CHV ORF5 Site (
FIG. 13 ) - Plasmid pPB208 (Example 7.1.) was digested with SmaI and ApaI to isolate a 2909-bp SmaI-ApaI fragment containing the cassette for the expression of the CDV HA gene. This fragment was then ligated with plasmid pPB202 (Example 4), previously digested with EcoRV and ApaI, to give plasmid pPB216 (6291 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF5 site.
- Construction of the Donor Plasmid pPB217 for the Insertion of the CDV EA Expression Cassette Into the CHV TK Site (
FIG. 14 ) - Plasmid pPB208 (Example 7.1.) was digested with ApaI and ClaI to isolate a 2920-bp fragment containing the cassette for the expression of the CDV HA gene. This fragment was ligated with plasmid pPB204 (Example 5), previously digested with ApaI and ClaI, to give plasmid pPB217 (6316 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the CHV TK site.
- Construction of the Donor Plasmid pPB218 for the Insertion of the CDV HA Expression Cassette Into the Site Situated Between the CHV ORF19 and CHV ORF22 Genes (
FIG. 15 ) - Plasmid pPB208 (Example 7.1.) was digested with ApaI and ClaI to isolate a 2920-bp fragment containing the cassette for the expression of the CDV HA gene. This fragment was ligated with plasmid pPB206 (Example 6), previously digested with ApaI and ClaI, to give plasmid pPB218 (6462 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the site situated between the CHV ORF19 and CHV ORF22 genes.
- Isolation of the Recombinant Virus vCHV01 Containing the Cassette for the Expression of the CDV HA Gene in the CHV ORF3 Site.
- Plasmid pPB213 (see Example 8) was linearized by digestion with HindIII, extracted with a phenol-chloroform mixture, precipitated with absolute ethanol and then taken up in sterile water.
- MDCK cells forming a well-established cell lawn in a Petri dish (Corning 4.5 cm in diameter) were then transfected with the following mixture: 1 μg of linearized plasmid pPB213+5 μg of CHV viral DNA in 300 μl of MEM medium and 100 μg of LipofectAMINE (Gibco-BRL Cat# 18324-012) diluted in 300 μl of medium (final volume of the mixture=600 μl). These 600 μl were then diluted in 3 ml (final volume) of MEM medium and spread over 3×106 MDCK cells. The mixture was left in contact with the cells for 5 hours, then removed and replaced by 5 ml of culture medium. The cells were then left in culture for 24 hours at +37° C. After 24 hours to 48 hours of culture, 1 ml of culture supernatant was harvested, and several dilutions of this supernatant were used to infect other MDCK cells (cultured in Petri dishes (Corning 4.5 cm in diameter)) so as to obtain isolated plaques, each dish being infected with 1 ml of a dilution of the initial supernatant. After contact for 1 hour at 37° C., the infection medium was removed and replaced by 5 ml of MEM medium containing 1% of agarose, kept supercooled at 42° C. When the agarose had solidified, the dishes were incubated for 48 hours at 37° C. in a CO2 incubator until plaques were seen. The agarose layer was then removed, and a transfer of the viral plaques was carried out onto a sterile nitrocellulose membrane of the same diameter as the Petri dish used for culturing. This membrane was itself transferred onto another nitrocellulose membrane so as to obtain an inverted “copy” of the first transfer. The plaques transferred onto this second copy were then hybridized, according to the standard techniques known to a person skilled in the art, with a 1842-bp NotI-NotI fragment of the CDV HA gene, obtained by digestion of plasmid pPB208 (Example 7.1.), labelled with digoxigenin (DNA Labelling kit, Boehringer Mannheim, CAT # 1175033). After hybridization, washes and contacting with the visualization substrate, the nitrocellulose membrane was placed in contact with an autoradiographic film. The images of positive hybridization on this membrane indicated which plaques were the ones which contained recombinant CHV viruses which had inserted the CDV HA cassette. The plaques corresponding to these positive plaques were cut out under sterile conditions from the first nitrocellulose membrane, placed in an Eppendorf tube containing 0.5 ml of MEM medium and sonicated to release the virions from the membrane. The medium contained in the Eppendorf tube was then diluted in MEM medium, and the dilutions thereby obtained were used to infect further cultures of MDCK cells. A 100% pure recombinant virus containing the HCMV-IE/CDV HA/polyA cassette inserted into the ORF3 site was thereby isolated after 3 cycles of purification, and was called vCHV01. The homology of the recombination was verified by PCR using oligonucleotides situated on each side of the insertion site. The absence of reorganization on the genome of the recombinant virus vCHV01, other than in the recombination region, was verified by the Southern blot technique.
- Isolation of Recombinant CHV Viruses Expressing Various Foreign Genes
- According to the procedure described in Example 14, the construction of different recombinant CHV viruses is carried out using the donor plasmids described in Examples 9 to 13.
- Preparation of the Vaccines
- To prepare a vaccine, the recombinant viruses obtained in Examples 14 and 15 are cultured on MDCK cells. Harvesting of the recombinant virus takes place when the cytopathic effect is complete. The lysed cells and the culture supernatant are harvested. After clarification of the cell lysate to remove cell debris, the viral solution is titrated. The viral solution is then diluted in a stabilizing solution for lyophilization, distributed on the basis of one vaccinal dose (102 CCID50 to 107 CCID50) per vial and lastly lyophilized. The viral solution can then be frozen if necessary.
- Vaccination Methods
- According to the preferred mode of vaccination, the vaccine obtained according to the invention is redissolved or thawed, and then administered via the parenteral or mucosal route, but preferably via the mucosal, in particular the oral and/or nasal, route. The vaccinal dose will preferably be between 102 CCID50 and 107 CCID50. Preferably, the dose for the parenteral route will be between 104 CCID50 and 107 CCID50, and for the oral and/or nasal route, between 102 CCID50 and 105 CCID50. As defined, the vaccine is effective in general after a single administration via the oral and/or nasal route. However, repeated administrations may be necessary.
Claims (32)
1-16. (canceled)
17. A recombinant canine herpes virus (CHV) comprising and expressing at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase.
18. The recombinant CHV according to claim 17 wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB.
19. The recombinant CHV of claim 17 wherein the at least one heterologous nucleotide sequence is inserted by simple insertion, or after total or partial deletion of the insertion locus.
20. The recombinant CHV according to claim 17 further comprising a strong eukaryotic promoter; wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter.
21. The recombinant CHV according to claim 20 wherein the strong eukaryotic promoter comprises a CMV immediate-early promoter.
22. The recombinant CHV of claim 21 wherein the CMV immediate-early promoter comprises a murine or human CMV immediate-early promoter.
23. The recombinant CHV according to claim 17 comprising at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter.
24. The recombinant CHV according to claim 23 wherein the eukaryotic promoters are CMV immediate-early promoters of different animal origin.
25. The recombinant CHV according to claim 23 comprising a first heterologous nucleotide sequence operably linked to a first promoter and a second heterologous nucleotide sequence operably linked to a second promoter; wherein, the first promoter comprises a CMV immediate-early promoter, and, the first and second promoters are arranged so that their 5′ ends are adjacent.
26. The recombinant CHV according to claim 18 further comprising at least one heterologous nucleotide sequence encoding an immunomodulatory polypeptide.
27. The recombinant CHV according to claim 25 wherein the heterologous nucleotide sequence comprises a nucleotide sequence selected from the group consisting of nucleotide sequences encoding cytokines.
28. The recombinant CHV according to claim 17 wherein the heterologous nucleotide sequence comprises an expression cassette comprising from 5′ to 3′, a promoter, two or more coding regions separated in pairs by an internal ribosome entry site (IRES), and a polyadenylation signal.
29. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the canine distemper virus HA antigen.
30. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the canine distemper virus F antigen.
31. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the rabies virus G antigen.
32. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the canine parvovirus VP2 antigen.
33. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the parainfluenza virus type 2 HA antigen.
34. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the parainfluenza virus type 2 F antigen.
35. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the Borrelia burgdorferi OspA antigen.
36. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the Borrelia burgdorferi OspB antigen.
37. The recombinant CHV according to claim 17 wherein the at least one heterologous nucleotide sequence encodes an antigen.
38. The recombinant CHV according to claim 17 wherein the at least one heterologous nucleotide sequence encodes an immunomodulatory polypeptide.
39. An immunological composition comprising a recombinant CHV; wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence is inserted by simple insertion, or after total or partial deletion of the insertion locus or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase andwherein the recombinant CHV further comprises a strong eukaryotic promoter; wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV further comprises a strong eukaryotic promoter, wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter and wherein the strong eukaryotic promoter comprises a CMV immediate-early promoter orwherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV further comprises a strong eukaryotic promoter, wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter, wherein the strong eukaryotic promoter comprises a CMV immediate-early promoter and wherein the CMV immediate-early promoter comprises a murine or human CMV immediate-early promoter or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter and wherein the eukaryotic promoters are CMV immediate-early promoters of different animal origin or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter and wherein the recombinant CHV comprises a first heterologous nucleotide sequence operably linked to a first promoter and a second heterologous nucleotide sequence operably linked to a second promoter, wherein, the first promoter comprises a CMV immediate-early promoter, and, the first and second promoters are arranged so that their 5′ ends are adjacent or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV further comprises at least one heterologous nucleotide sequence encoding an immunomodulatory polypeptide or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter, wherein the recombinant CHV comprises a first heterologous nucleotide sequence operably linked to a first promoter and a second heterologous nucleotide sequence operably linked to a second promoter; wherein, the first promoter comprises a CMV immediate-early promoter, and, the first and second promoters are arranged so that their 5′ ends are adjacent and wherein the heterologous nucleotide sequence comprises a nucleotide sequence selected from the group consisting of nucleotide sequences encoding cytokines or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the heterologous nucleotide sequence comprises an expression cassette comprising from 5′ to 3′, a promoter, two or more coding regions separated in pairs by an internal ribosome entry site (IRES), and a polyadenylation signal orwherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the canine distemper virus HA antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the canine distemper virus F antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the rabies virus G antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the canine parvovirus VP2 antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the parainfluenza virus type 2 HA antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the parainfluenza virus type 2 F antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the Borrelia burgdorferi OspA antigen orwherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the Borrelia burgdorferi OspB antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence encodes an antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence encodes an immunomodulatory polypeptide.
40. A multivalent immunological composition comprising, as a mixture or to be admixed, at least a first recombinant CHV and a second recombinant CHV; wherein the heterologous nucleotide sequence in the first recombinant CHV is different than the heterologous nucleotide sequence in the second recombinant CHV; wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence is inserted by simple insertion, or after total or partial deletion of the insertion locus or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase andwherein the recombinant CHV further comprises a strong eukaryotic promoter; wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV further comprises a strong eukaryotic promoter, wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter and wherein the strong eukaryotic promoter comprises a CMV immediate-early promoter orwherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV further comprises a strong eukaryotic promoter, wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter, wherein the strong eukaryotic promoter comprises a CMV immediate-early promoter and wherein the CMV immediate-early promoter comprises a murine or human CMV immediate-early promoter or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter and wherein the eukaryotic promoters are CMV immediate-early promoters of different animal origin or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter and wherein the recombinant CHV comprises a first heterologous nucleotide sequence operably linked to a first promoter and a second heterologous nucleotide sequence operably linked to a second promoter, wherein, the first promoter comprises a CMV immediate-early promoter, and, the first and second promoters are arranged so that their 5′ ends are adjacent or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV further comprises at least one heterologous nucleotide sequence encoding an immunomodulatory polypeptide or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter, wherein the recombinant CHV comprises a first heterologous nucleotide sequence operably linked to a first promoter and a second heterologous nucleotide sequence operably linked to a second promoter; wherein, the first promoter comprises a CMV immediate-early promoter, and, the first and second promoters are arranged so that their 5′ ends are adjacent and wherein the heterologous nucleotide sequence comprises a nucleotide sequence selected from the group consisting of nucleotide sequences encoding cytokines or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the heterologous nucleotide sequence comprises an expression cassette comprising from 5′ to 3′, a promoter, two or more coding regions separated in pairs by an internal ribosome entry site (IRES), and a polyadenylation signal orwherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the canine distemper virus HA antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the canine distemper virus F antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the rabies virus G antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the canine parvovirus VP2 antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the parainfluenza virus type 2 HA antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the parainfluenza virus type 2 F antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the Borrelia burgdorferi OspA antigen orwherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the Borrelia burgdorferi OspB antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence encodes an antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence encodes an immunomodulatory polypeptide.
41. A method for inducing an immunological response in a canine comprising administering to the canine a recombinant CHV as claimed in any one of claims 17 to 36 or 37 or 38.
42. A method for inducing an immunological response in a canine animal comprising administering to the canine an immunological composition as claimed in claim 39 .
43. A method for inducing an immunological response in a canine comprising administering to the canine an immunological composition as claimed in claim 40 .
44. The method of claim 41 wherein the administering comprises mucosally administering a dose comprising between 102 and 105 CCID50 of the recombinant CHV.
45. The method of claim 42 wherein the administering comprises mucosally administering a dose comprising between 102 and 105 CCID50 of the recombinant CHV.
46. The method of claim 43 wherein the administering comprises mucosally administering a dose comprising between 102 and 105 CCID50 of the recombinant CHV.
47. A method for expressing a polypeptide comprising contacting a suitable cell with a recombinant CHV as claimed in any one of claims 17 to 36 or 37 or 38.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/935,494 US20060024329A1 (en) | 1996-06-27 | 2004-09-07 | Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2. |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR96/08242 | 1996-06-27 | ||
FR9608242A FR2750865B1 (en) | 1996-06-27 | 1996-06-27 | RECOMBINANT LIVING VACCINE BASED ON CANINE HERPESVIRUS, IN PARTICULAR FOR SQUARE DISEASE, RABIES OR TYPE 2 PARAINFLUENZA VIRUS |
PCT/FR1997/001115 WO1997049825A1 (en) | 1996-06-27 | 1997-06-23 | Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus |
US09/213,053 US6159477A (en) | 1996-06-27 | 1998-12-16 | Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus |
US59647900A | 2000-06-19 | 2000-06-19 | |
US10/935,494 US20060024329A1 (en) | 1996-06-27 | 2004-09-07 | Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2. |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US59647900A Continuation | 1996-06-27 | 2000-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060024329A1 true US20060024329A1 (en) | 2006-02-02 |
Family
ID=9493648
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/213,053 Expired - Lifetime US6159477A (en) | 1996-06-27 | 1998-12-16 | Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus |
US10/935,494 Abandoned US20060024329A1 (en) | 1996-06-27 | 2004-09-07 | Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/213,053 Expired - Lifetime US6159477A (en) | 1996-06-27 | 1998-12-16 | Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus |
Country Status (13)
Country | Link |
---|---|
US (2) | US6159477A (en) |
EP (1) | EP0910657B1 (en) |
JP (1) | JP2000512264A (en) |
KR (1) | KR20000022213A (en) |
AU (1) | AU737583B2 (en) |
BR (1) | BR9710012B1 (en) |
CA (1) | CA2258735C (en) |
CZ (1) | CZ297022B6 (en) |
FR (1) | FR2750865B1 (en) |
NZ (1) | NZ333546A (en) |
PL (2) | PL196247B1 (en) |
WO (1) | WO1997049825A1 (en) |
ZA (1) | ZA975619B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110302374A (en) * | 2019-08-09 | 2019-10-08 | 中国农业科学院特产研究所 | Canine vaccine and its preparation method and application |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2750865B1 (en) * | 1996-06-27 | 1998-12-04 | Rhone Merieux | RECOMBINANT LIVING VACCINE BASED ON CANINE HERPESVIRUS, IN PARTICULAR FOR SQUARE DISEASE, RABIES OR TYPE 2 PARAINFLUENZA VIRUS |
FR2775601B1 (en) * | 1998-03-03 | 2001-09-21 | Merial Sas | RECOMBINANT LIVING VACCINES AND ADJUVANTS |
US7906311B2 (en) | 2002-03-20 | 2011-03-15 | Merial Limited | Cotton rat lung cells for virus culture |
EP2158917A1 (en) | 2002-09-19 | 2010-03-03 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | P.ariasi polypeptides, P.perniciosus polypeptides and methods of use |
WO2004039958A2 (en) | 2002-10-29 | 2004-05-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Lutzomyia longipalpis polypeptides and methods of use |
CA2510189A1 (en) * | 2002-12-19 | 2004-07-08 | Thomas Gore | Trivalent vaccine with maternal antibody transfer via the milk |
EP1606419A1 (en) | 2003-03-18 | 2005-12-21 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
JP4750024B2 (en) | 2003-06-20 | 2011-08-17 | プロテイン サイエンシーズ コーポレイション | Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, and methods and assays for their production and use |
ES2417019T3 (en) | 2003-11-13 | 2013-08-05 | University Of Georgia Research Foundation, Inc. | Characterization procedure of infectious bursitis disease virus |
NZ549384A (en) | 2004-02-19 | 2008-08-29 | Univ Alberta | Leptin promoter polymorphisms and uses thereof |
EP2198881A1 (en) | 2005-04-25 | 2010-06-23 | Merial Limited | Nipah virus vaccines |
US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
CN101312742B (en) * | 2005-09-16 | 2012-07-25 | 梅瑞尔有限公司 | Stabilizers for freeze-dried vaccines |
EP2186823A1 (en) | 2005-11-14 | 2010-05-19 | Merial Limited | Gene therapy for renal failure |
US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
EP2283035B1 (en) | 2008-05-08 | 2015-07-29 | Merial Limited | Leishmania vaccine using sand fly salivary immunogen |
WO2010115133A2 (en) | 2009-04-03 | 2010-10-07 | Merial Limited | Newcastle disease virus vectored avian vaccines |
US20130197612A1 (en) | 2010-02-26 | 2013-08-01 | Jack W. Lasersohn | Electromagnetic Radiation Therapy |
WO2012030720A1 (en) | 2010-08-31 | 2012-03-08 | Merial Limited | Newcastle disease virus vectored herpesvirus vaccines |
WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
EP2694678A2 (en) | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
US20140296248A1 (en) | 2011-04-04 | 2014-10-02 | Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
US9216213B2 (en) | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
EP2701736A1 (en) | 2011-04-25 | 2014-03-05 | Advanced Bioscience Laboratories, Inc. | Truncated hiv envelope proteins (env), methods and compositions related thereto |
CA2837375C (en) | 2011-06-01 | 2019-07-16 | Merial Limited | Needle-free administration of prrsv vaccines |
LT2741740T (en) | 2011-08-12 | 2017-08-10 | Merial, Inc. | Vacuum-assisted preservation of biological products, in particular of vaccines |
WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
EP2968514A1 (en) | 2013-03-12 | 2016-01-20 | Merial, Inc. | Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
CN106456724A (en) | 2013-12-20 | 2017-02-22 | 博德研究所 | Combination therapy with neoantigen vaccine |
CA2966191A1 (en) | 2014-11-03 | 2016-05-12 | Merial, Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
CA2986235A1 (en) | 2015-05-20 | 2016-11-24 | The Broad Institute, Inc. | Shared neoantigens |
TW202241500A (en) | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | Formulations for neoplasia vaccines and methods of preparing thereof |
CN107922462B (en) | 2015-06-23 | 2022-03-18 | 勃林格殷格翰动物保健美国公司 | Recombinant virus vector containing PRRSV minor protein and its production process and use |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
EP3478066A1 (en) * | 2016-06-30 | 2019-05-08 | Next Science IP Holdings Pty Ltd | Antimicrobial compositions and methods employing same |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
CN114790229B (en) * | 2022-04-12 | 2024-07-12 | 北京慧德易科技有限责任公司 | Recombinant protein and preparation method and application thereof |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4213965A (en) * | 1979-01-23 | 1980-07-22 | Cornell Research Foundation, Inc. | Small-plaque variant canine herpesvirus vaccine |
US5356622A (en) * | 1991-12-13 | 1994-10-18 | Paravax, Inc. | Flea midgut-supernatant vaccines |
US5399485A (en) * | 1992-01-17 | 1995-03-21 | United States Of America | Methods and compositions for diagnosing cat scratch disease and bacillary angiomatosis caused by Rochalimaea henselae |
US5418137A (en) * | 1991-09-26 | 1995-05-23 | Paravax, Inc. | Flea membrane binding site proteins as screening tools |
US5681724A (en) * | 1995-11-16 | 1997-10-28 | Heska Corporation | Parasitic helminth macrophage inhibitory factor nucleic acid molecules and uses thereof |
US5707817A (en) * | 1993-02-05 | 1998-01-13 | Colorado State University Research Foundation | Carbohydrate-based vaccine and diagnostic reagent for trichinosis |
US5753235A (en) * | 1996-02-15 | 1998-05-19 | Heska Corporation | Recombinant canine herpesviruses |
US5777095A (en) * | 1988-10-24 | 1998-07-07 | Symbicom Aktiebolag | Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90 |
US5789194A (en) * | 1995-05-23 | 1998-08-04 | Heska Corporation | Parasitic helminth venom allergen antigen 5-like genes and proteins |
US5795768A (en) * | 1991-02-12 | 1998-08-18 | Heska Corporation | Filariid nematode cysteine protease proteins, nucleic acid molecules and uses thereof |
US5843456A (en) * | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
US6159477A (en) * | 1996-06-27 | 2000-12-12 | Merial | Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2659349B1 (en) * | 1990-03-12 | 1993-12-24 | Rhone Merieux | RECOMBINANT HERPIC VIRUSES ESPECIALLY FOR THE PRODUCTION OF VACCINES, THEIR PREPARATION PROCESS, THE PLASMIDS MADE DURING THIS PROCESS AND THE VACCINES OBTAINED. |
CA2103788A1 (en) * | 1991-02-12 | 1992-08-13 | Robert B. Grieve | Reagents and methods for identification of vaccines |
US5639876A (en) * | 1991-02-12 | 1997-06-17 | Heska Corporation | Nucleic acid molecules encoding novel parasitic helminth proteins |
AU675214B2 (en) * | 1991-11-12 | 1997-01-30 | Colorado State University Research Foundation | Protease vaccine against heartworm |
WO1996011706A1 (en) * | 1994-10-18 | 1996-04-25 | Heska Corporation | Use of flea proteases and protease inhibitors to protect animals from flea infestation |
US5492695A (en) * | 1992-05-14 | 1996-02-20 | Colorado State University Research Foundation | Vaccinating cats against Dirofilaria immitis with an L4 homogenate |
US5541075A (en) * | 1993-02-05 | 1996-07-30 | Heska Corporation | Carbohydrate-based vaccine and diagnostic reagent for trichinosis |
WO1994017813A1 (en) * | 1993-02-08 | 1994-08-18 | Paravax, Inc. | Defective sindbis virus vectors that express toxoplasma gondii p30 antigens |
US5569603A (en) * | 1994-03-08 | 1996-10-29 | Heska Corporation | Dirofilaria immitis GP29 proteins, nucleic acid molecules and uses thereof |
DE69535561T2 (en) * | 1994-03-30 | 2008-06-05 | Connaught Technology Corp., Greenville | NUCLEOTIDE AND AMINO ACID SEQUENCES gB, gC AND gD OF THE HERPESVIRUS OF THE DOG AND THEIR USES |
EP0766693A4 (en) * | 1994-05-26 | 2002-10-30 | Heska Corp | Novel parasite protease genes and proteins |
CA2201482C (en) * | 1994-10-07 | 2011-04-26 | Glenn R. Frank | Novel ectoparasite saliva proteins and apparatus to collect such proteins |
CN1117081A (en) * | 1995-03-16 | 1996-02-21 | 高云 | Triple live vaccine and toxin vaccine for distemper, rabies and pavovirus and its preparing method |
-
1996
- 1996-06-27 FR FR9608242A patent/FR2750865B1/en not_active Expired - Lifetime
-
1997
- 1997-06-23 CZ CZ0428198A patent/CZ297022B6/en not_active IP Right Cessation
- 1997-06-23 EP EP97930568A patent/EP0910657B1/en not_active Expired - Lifetime
- 1997-06-23 PL PL330879A patent/PL196247B1/en unknown
- 1997-06-23 PL PL380134A patent/PL196530B1/en unknown
- 1997-06-23 AU AU34474/97A patent/AU737583B2/en not_active Expired
- 1997-06-23 KR KR1019980710632A patent/KR20000022213A/en not_active Withdrawn
- 1997-06-23 NZ NZ333546A patent/NZ333546A/en not_active IP Right Cessation
- 1997-06-23 CA CA2258735A patent/CA2258735C/en not_active Expired - Lifetime
- 1997-06-23 BR BRPI9710012-9A patent/BR9710012B1/en not_active IP Right Cessation
- 1997-06-23 JP JP09532942A patent/JP2000512264A/en active Pending
- 1997-06-23 WO PCT/FR1997/001115 patent/WO1997049825A1/en active IP Right Grant
- 1997-06-25 ZA ZA975619A patent/ZA975619B/en unknown
-
1998
- 1998-12-16 US US09/213,053 patent/US6159477A/en not_active Expired - Lifetime
-
2004
- 2004-09-07 US US10/935,494 patent/US20060024329A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4213965A (en) * | 1979-01-23 | 1980-07-22 | Cornell Research Foundation, Inc. | Small-plaque variant canine herpesvirus vaccine |
US5777095A (en) * | 1988-10-24 | 1998-07-07 | Symbicom Aktiebolag | Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90 |
US5795768A (en) * | 1991-02-12 | 1998-08-18 | Heska Corporation | Filariid nematode cysteine protease proteins, nucleic acid molecules and uses thereof |
US5843456A (en) * | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
US5418137A (en) * | 1991-09-26 | 1995-05-23 | Paravax, Inc. | Flea membrane binding site proteins as screening tools |
US5356622A (en) * | 1991-12-13 | 1994-10-18 | Paravax, Inc. | Flea midgut-supernatant vaccines |
US5399485A (en) * | 1992-01-17 | 1995-03-21 | United States Of America | Methods and compositions for diagnosing cat scratch disease and bacillary angiomatosis caused by Rochalimaea henselae |
US5707817A (en) * | 1993-02-05 | 1998-01-13 | Colorado State University Research Foundation | Carbohydrate-based vaccine and diagnostic reagent for trichinosis |
US5789194A (en) * | 1995-05-23 | 1998-08-04 | Heska Corporation | Parasitic helminth venom allergen antigen 5-like genes and proteins |
US5681724A (en) * | 1995-11-16 | 1997-10-28 | Heska Corporation | Parasitic helminth macrophage inhibitory factor nucleic acid molecules and uses thereof |
US5753235A (en) * | 1996-02-15 | 1998-05-19 | Heska Corporation | Recombinant canine herpesviruses |
US5804197A (en) * | 1996-02-15 | 1998-09-08 | Heska Corporation | Recombinant canine herpesviruses |
US6159477A (en) * | 1996-06-27 | 2000-12-12 | Merial | Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110302374A (en) * | 2019-08-09 | 2019-10-08 | 中国农业科学院特产研究所 | Canine vaccine and its preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
PL196530B1 (en) | 2008-01-31 |
NZ333546A (en) | 2001-06-29 |
JP2000512264A (en) | 2000-09-19 |
BR9710012A (en) | 1999-08-10 |
WO1997049825A1 (en) | 1997-12-31 |
ZA975619B (en) | 1998-12-28 |
EP0910657A1 (en) | 1999-04-28 |
FR2750865A1 (en) | 1998-01-16 |
CA2258735C (en) | 2011-06-21 |
PL196247B1 (en) | 2007-12-31 |
CZ297022B6 (en) | 2006-08-16 |
AU737583B2 (en) | 2001-08-23 |
FR2750865B1 (en) | 1998-12-04 |
PL330879A1 (en) | 1999-06-07 |
CZ428198A3 (en) | 1999-04-14 |
BR9710012B1 (en) | 2011-10-18 |
US6159477A (en) | 2000-12-12 |
KR20000022213A (en) | 2000-04-25 |
AU3447497A (en) | 1998-01-14 |
EP0910657B1 (en) | 2013-02-27 |
CA2258735A1 (en) | 1997-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU737583B2 (en) | Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2 | |
US6586412B2 (en) | Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies | |
AU739374B2 (en) | Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus | |
US6387376B1 (en) | Recombinant vaccine containing feline herpes virus type 1 particularly for treating feline infectious peritonitis | |
AU734085B2 (en) | Recombinant live avian vaccine, using as vector the avian infectious laryngotracheitis virus. | |
US6376473B1 (en) | Polynucleotide vaccine formula in particular against bovine respiratory pathology | |
AU708077B2 (en) | Live recombinant avian vaccine using an avian herpesvirus as vector | |
AU735265B2 (en) | Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus | |
CA2223029A1 (en) | Canine parvovirus dna vaccines | |
EP0606452B1 (en) | Vector vaccines of recombinant feline herpesvirus | |
WO1995007987A2 (en) | Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor | |
US7294338B2 (en) | Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |